Sudden or Cardiac Deaths on Ibrutinib-Based Therapy were associated with a prior History of Hypertension or Cardiac Disease and the use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
Authors
Munir, T.Pitchford, A.
Bloor, A.
Broom, A.
Young, M.
Kennedy, B.
Walewska, R.
Furtado, M.
Preston, G.
Neilson, J.
Pemberton, N.
Sidra, G.
Morley, N.
Cwynarski, K.
Schuh, A.
Forconi, F.
Gatto, S.
Paneesha, S.
Fox, C.
Howard, D.
Hockaday, A.
Cairns, D.
Jackson, S.
Greatorex, N.
Patten, P. E. M.
Allsup, D.
Hillmen, P.
Issue Date
2022